Dr. Getz's research is focused on the treatment and supportive care of children and young adults with cancer, and on understanding and balancing the associated therapeutic benefits and toxicity risks, with an emphasis in cardio-oncology. Her overarching research goal is to develop and apply advanced epidemiologic methods to existing data resources in creative ways to enable observational research studies that will impact practice. She hopes that her research will address treatment and outcome disparities, and improve both clinical outcomes and quality of life for pediatric cancer patients across diagnoses, during treatment, and into survivorship.
Her Alex's Lemonade Stand Foundation Young Investigator Award evaluates risk factors for cardiac dysfunction during AML therapy and assesses novel early indicators of cardiotoxicity to identify patients at the highest risk before they progress to overt irreversible cardiomyopathy.
Her NHLBI K01 leverages the strengths of multiple complementary data resources including the clinical trial data, administrative billing data, echocardiographic studies, and large volume electronic health record data to address important questions across the cardiotoxicity risk continuum.